Fair Competition

CSL's GCC is responsible for providing strategic direction to CSL's fair competition compliance activities and monitoring the implementation and evolution of global fair competition compliance initiatives. We ensure fair competition across all geographies and business units by advocating a culture involving the strict exclusion of practices that would mislead consumers, contravene applicable trade practices or competition laws, or constitute unfair practices. The organisation seeks to avoid any breaches of regulations or industry codes of conduct by recognising the importance of competing fairly in the global marketplace and ensuring equitable access to patient therapies and vaccines.

In 2015/16, there were no findings against CSL relating to a breach of any fair trading or competition laws, other than the following:

  • Seqirus USA Inc. (formerly bioCSL Inc.) entered into a Consent Order with the State of Alabama Pharmacy Board. In 2015, Seqirus failed to renew its State Distribution License prior to distributing vaccine in Alabama. As a result, in May 2016, Seqirus admitted that it had distributed a pharmaceutical without the requisite licence and paid an administrative fine.
  • In December 2015, CSL Behring S.A. (Argentina), and a number of other companies and individuals, was found by the Argentinian Antitrust Authority (CNDC) to have participated in bid rigging in certain public hospital product tenders in the gelatine market between 2005 and 2007. CSL Behring was fined ARS 10 million (at that time approximately US$1 million). CSL Behring believes that there is no basis for the decision and has appealed.